<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T2" position="float">
 <label>Table 2</label>
 <caption>
  <p>Mortality rate ratios (95% confidence interval) compared with Europe by duration on antiretroviral therapy.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <td rowspan="1" colspan="1">Mortality rate ratio</td>
    <td colspan="5" rowspan="1">Duration on antiretroviral therapy (months)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"/>
    <td rowspan="1" colspan="1">0–3</td>
    <td rowspan="1" colspan="1">3–6</td>
    <td rowspan="1" colspan="1">6–12</td>
    <td rowspan="1" colspan="1">12–24</td>
    <td rowspan="1" colspan="1">24–48</td>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="6" rowspan="1">East Africa</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Noncorrected</td>
    <td rowspan="1" colspan="1">3.74 (3.08–4.54)</td>
    <td rowspan="1" colspan="1">2.25 (1.81–2.81)</td>
    <td rowspan="1" colspan="1">1.89 (1.54–2.33)</td>
    <td rowspan="1" colspan="1">1.41 (1.18–1.67)</td>
    <td rowspan="1" colspan="1">1.04 (0.89–1.22)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Corrected
     <xref ref-type="table-fn" rid="TF2-1">
      <sup>a</sup>
     </xref>
    </td>
    <td rowspan="1" colspan="1">8.25 (6.69–10.17)</td>
    <td rowspan="1" colspan="1">4.76 (3.71–6.11)</td>
    <td rowspan="1" colspan="1">4.73 (3.74–5.98)</td>
    <td rowspan="1" colspan="1">4.33 (3.58–5.24)</td>
    <td rowspan="1" colspan="1">4.10 (3.45–4.88)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Corrected and adjusted for baseline patient characteristics
     <xref ref-type="table-fn" rid="TF2-2">
      <sup>b</sup>
     </xref>
    </td>
    <td rowspan="1" colspan="1">7.25 (5.87–8.97)</td>
    <td rowspan="1" colspan="1">4.24 (3.30–5.46)</td>
    <td rowspan="1" colspan="1">4.24 (3.35–5.37)</td>
    <td rowspan="1" colspan="1">3.89 (3.21 – 4.72)</td>
    <td rowspan="1" colspan="1">3.63 (3.04–4.33)</td>
   </tr>
   <tr>
    <td colspan="6" rowspan="1">West Africa</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Noncorrected</td>
    <td rowspan="1" colspan="1">4.22 (3.42–5.21)</td>
    <td rowspan="1" colspan="1">2.00 (1.55–2.60)</td>
    <td rowspan="1" colspan="1">1.98 (1.55–2.52)</td>
    <td rowspan="1" colspan="1">1.95 (1.61–2.36)</td>
    <td rowspan="1" colspan="1">1.59 (1.33–1.90)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Corrected
     <xref ref-type="table-fn" rid="TF2-3">
      <sup>c</sup>
     </xref>
    </td>
    <td rowspan="1" colspan="1">9.30 (7.63–11.32)</td>
    <td rowspan="1" colspan="1">4.23 (3.36–5.34)</td>
    <td rowspan="1" colspan="1">4.94 (4.00–6.11)</td>
    <td rowspan="1" colspan="1">6.01 (5.09–7.09)</td>
    <td rowspan="1" colspan="1">6.28 (5.43–7.26)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Corrected and adjusted by age at ART initiation</td>
    <td rowspan="1" colspan="1">9.73 (7.99–11.85)</td>
    <td rowspan="1" colspan="1">4.50 (3.57–5.67)</td>
    <td rowspan="1" colspan="1">5.10 (4.12–6.31)</td>
    <td rowspan="1" colspan="1">6.09 (5.16–7.19)</td>
    <td rowspan="1" colspan="1">6.42 (5.55–7.43)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Corrected and adjusted by age and period of ART initiation</td>
    <td rowspan="1" colspan="1">8.95 (7.34–10.91)</td>
    <td rowspan="1" colspan="1">4.05 (3.21–5.11)</td>
    <td rowspan="1" colspan="1">4.38 (3.54–5.43)</td>
    <td rowspan="1" colspan="1">5.37 (4.54–6.35)</td>
    <td rowspan="1" colspan="1">5.61 (4.84–6.51)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Corrected and adjusted by age, period of ART initiation and CD4
     <sup>+</sup> in patients with available CD4
     <sup>+</sup>
    </td>
    <td rowspan="1" colspan="1">3.42 (2.53–4.62)</td>
    <td rowspan="1" colspan="1">1.44 (0.94–2.19)</td>
    <td rowspan="1" colspan="1">2.07 (1.46–2.94)</td>
    <td rowspan="1" colspan="1">2.42 (1.86–3.15)</td>
    <td rowspan="1" colspan="1">2.49 (1.98–3.14)</td>
   </tr>
   <tr>
    <td colspan="6" rowspan="1">South Africa</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Crude</td>
    <td rowspan="1" colspan="1">6.25 (5.13–7.62)</td>
    <td rowspan="1" colspan="1">3.63 (2.89–4.56)</td>
    <td rowspan="1" colspan="1">4.37 (3.54–5.39)</td>
    <td rowspan="1" colspan="1">3.57 (3.01–4.24)</td>
    <td rowspan="1" colspan="1">4.16 (3.57–4.83)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Adjusted for baseline patient characteristics
     <xref ref-type="table-fn" rid="TF2-2">
      <sup>b</sup>
     </xref>
    </td>
    <td rowspan="1" colspan="1">5.42 (4.43–6.64)</td>
    <td rowspan="1" colspan="1">3.15 (2.50–3.97)</td>
    <td rowspan="1" colspan="1">3.77 (3.05–4.67)</td>
    <td rowspan="1" colspan="1">3.05 (2.56–3.63)</td>
    <td rowspan="1" colspan="1">3.47 (2.97–4.06)</td>
   </tr>
   <tr>
    <td colspan="6" rowspan="1">South America</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Crude</td>
    <td rowspan="1" colspan="1">5.19 (3.45–7.81)</td>
    <td rowspan="1" colspan="1">1.93 (0.98–3.83)</td>
    <td rowspan="1" colspan="1">3.13 (1.88–5.22)</td>
    <td rowspan="1" colspan="1">1.95 (1.19–3.22)</td>
    <td rowspan="1" colspan="1">2.84 (1.93–4.16)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Adjusted for baseline patient characteristics
     <xref ref-type="table-fn" rid="TF2-2">
      <sup>b</sup>
     </xref>
    </td>
    <td rowspan="1" colspan="1">4.47 (2.97–6.72)</td>
    <td rowspan="1" colspan="1">1.67 (0.84–3.32)</td>
    <td rowspan="1" colspan="1">2.70 (1.62–4.52)</td>
    <td rowspan="1" colspan="1">1.69 (1.02–2.78)</td>
    <td rowspan="1" colspan="1">2.42 (1.65–3.55)</td>
   </tr>
   <tr>
    <td colspan="6" rowspan="1">North America</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Crude</td>
    <td rowspan="1" colspan="1">1.02 (0.62–1.67)</td>
    <td rowspan="1" colspan="1">1.46 (0.91–2.34)</td>
    <td rowspan="1" colspan="1">2.67 (1.88–3.81)</td>
    <td rowspan="1" colspan="1">3.95 (3.07–5.08)</td>
    <td rowspan="1" colspan="1">4.34 (3.47–5.42)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Adjusted for baseline patient characteristics
     <xref ref-type="table-fn" rid="TF2-2">
      <sup>b</sup>
     </xref>
    </td>
    <td rowspan="1" colspan="1">0.88 (0.53–1.44)</td>
    <td rowspan="1" colspan="1">1.25 (0.78–2.02)</td>
    <td rowspan="1" colspan="1">2.30 (1.61–3.27)</td>
    <td rowspan="1" colspan="1">3.40 (2.64–4.37)</td>
    <td rowspan="1" colspan="1">3.72 (2.97–4.65)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Additional adjustment for transmission category, HIV-RNA and AIDS prior to ART initiation</td>
    <td rowspan="1" colspan="1">0.69 (0.42–1.14)</td>
    <td rowspan="1" colspan="1">0.99 (0.62–1.60)</td>
    <td rowspan="1" colspan="1">1.80 (1.25–2.58)</td>
    <td rowspan="1" colspan="1">2.65 (2.03–3.44)</td>
    <td rowspan="1" colspan="1">2.86 (2.26–3.62)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Additional adjustment for transmission category, HIV-RNA, AIDS prior to ART initiation and race/ethnicity in patients with available info on race/ethnicity</td>
    <td rowspan="1" colspan="1">0.53 (0.31–0.89)</td>
    <td rowspan="1" colspan="1">0.92 (0.55–1.55)</td>
    <td rowspan="1" colspan="1">1.48 (0.99–2.22)</td>
    <td rowspan="1" colspan="1">2.39 (1.77–3.24)</td>
    <td rowspan="1" colspan="1">2.78 (2.11–3.66)</td>
   </tr>
   <tr>
    <td colspan="6" rowspan="1">Central America and Caribbean</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Crude</td>
    <td rowspan="1" colspan="1">11.27 (8.87–14.33)</td>
    <td rowspan="1" colspan="1">4.61 (3.31–6.42)</td>
    <td rowspan="1" colspan="1">3.28 (2.32–4.63)</td>
    <td rowspan="1" colspan="1">2.73 (2.04–3.65)</td>
    <td rowspan="1" colspan="1">2.88 (2.22–3.75)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1"> Adjusted for baseline patient characteristics
     <xref ref-type="table-fn" rid="TF2-2">
      <sup>b</sup>
     </xref>
    </td>
    <td rowspan="1" colspan="1">9.92 (7.79–12.63)</td>
    <td rowspan="1" colspan="1">4.12 (2.95–5.74)</td>
    <td rowspan="1" colspan="1">2.93 (2.07–4.15)</td>
    <td rowspan="1" colspan="1">2.43 (1.82–3.26)</td>
    <td rowspan="1" colspan="1">2.50 (1.92–3.26)</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn fn-type="other">
   <p>ART, antiretroviral therapy.</p>
  </fn>
  <fn fn-type="other" id="TF2-1">
   <p>
    <sup>a</sup>Mortality estimates corrected by using an inverse-probability-weighted estimator of the rate where weights are constant and equal to the inverse ratio of the patients who could be traced out of all patients who were lost to follow-up.
   </p>
  </fn>
  <fn fn-type="other" id="TF2-2">
   <p>
    <sup>b</sup>Baseline patient characteristics are age (&lt;30, 30–44, 45–59, ≥60 years), CD4
    <sup>+</sup> T-cell count (0–24, 25–49, 50–99, 100–199, 200–349, ≥350 cells/μl, unknown) and period of ART initiation (2000–2003, 2004–2007, 2008–2011, 2012–2014).
   </p>
  </fn>
  <fn fn-type="other" id="TF2-3">
   <p>
    <sup>c</sup>Mortality estimates corrected by using a modification of the approach by Brinkhof and colleagues, which uses inflation factors to account for mortality under-reporting, under the assumption that mortality under-ascertainment in West Africa was similar to that in East Africa. Death rates based on observed data were estimated for different durations on ART (0–3, 3–6, 6–12, 12–24, 24–48 months) and then multiplied by inflation factor for each specific duration on ART determined as the ratio of the lost-to-follow-up-adjusted death rates over the observed rates estimated within East African cohorts.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
